A clinical study of diffusion-weighted magnetic resonance imaging-based prediction of efficacy of chemoradiotherapy for esophageal carcinoma
Wang Lan,Liu Lihong,Han Chun,Tian Hua,Ren Xuejiao,Shi Gaofeng,Wang Qi,Gao Chao,Wang Guangda
Department of Radiation Oncology (Wang L,Liu LH,Han CH,Tain H,Ren XJ,Gao CH),Department of Image (Shi GF,Wang Q,Wang GD),Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China
Abstract： Objective To investigate the parameters of diffusion-weighted magnetic resonance imaging (DWMRI) for prediction of the efficacy of chemoradiotherapy (CRT) for esophageal squamous cell carcinoma (ESCC), to determine the optimal time point and threshold for prediction, and to provide a basis for clinical practice. Methods From 2010 to 2011, 38 patients with ESCC were consecutively enrolled as subjects. All patients received three-dimensional conformal radiotherapy with 60 Gy in 30 fractions for 6 weeks. They also received concurrent or consolidation chemotherapy (FP or TP scheme) as adjuvant treatment. Patients received DWMRI scans before radiotherapy and at weeks 1-6 during radiotherapy. The apparent diffusion coefficient (ADC) values and tumor lengths obtained from serial DWMRI scans were recorded and analyzed. Comparison was made by paired t test. Repeated measurements were analyzed by analysis of variance (ANOVA) and multivariate ANOVA. The prognosis was predicted by the Logistic model. The effectiveness analysis and threshold screening were performed using the receiver operating characteristic (ROC) curve. Results In all patients, 20(52.6%) had complete response (CR) and 18(47.4%) had partial response (PR). There were no significant differences in the ADC values before radiotherapy and at weeks 1-6 during radiotherapy between patients with CR and PR (1.82 vs. 1.42;1.92 vs. 1.49;2.06 vs. 1.67;2.35 vs. 1.79;2.62 vs. 2.11;2.71 vs. 2.18;2.96 vs. 2.28×10-3 mm2/s;P=0.006,0.003,0.012,0.001,0.003,0.008,0.002). The ADC value at third week during radiotherapy was the only independent prognostic factor for short-term treatment outcomes in patients with ESCC (OR=0.134, P=0.007). These results were also supported by the multivariate ANOVA analyses. The analysis of the ROC curve showed that at the third week during radiotherapy, the area under the ADC curve was the largest (Az=0.857) and the diagnostic effectiveness was the best;the threshold value, sensitivity, and specificity were 2.02×10-3 mm2/s, 80.0%, and 92.9%, respectively. Eight patients who had tumor out of control or recurrence within 1 year after treatment had the ADC curve fall down at the end of the fifth week and the reduction of tumor length substantially slow down from the fifth week. Conclusions DWMRI is an effective imaging approach for monitoring tumor response to CRT in patients with ESCC. The ADC value at the end of the third week during radiotherapy may be the optimal time point for prediction of treatment outcomes. The reduction in the ADC value or non-reduction in tumor length at the end of the treatment indicates a high risk of recurrence.
Wang Lan,Liu Lihong,Han Chun et al. A clinical study of diffusion-weighted magnetic resonance imaging-based prediction of efficacy of chemoradiotherapy for esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2016, 25(10): 1074-1078.
[1] Sun YS,Zhang XP,Tang L,et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy:preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging[J].Radiology,2010,254(1):170-178.DOI:10.1148/radiol.2541082230. [2] Cui Y,Zhang XP,Sun YS,et al. Apparent diffusion coefficient:potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases[J].Radiology,2008,248(3):894-900.DOI:10.1148/radiol.2483071407. [3] Nilsen L,Fangberget A,Geier O,et al. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy[J].Acta Oncol,2010,49(3):354-360.DOI:10.3109/02841861003610184. [4] Harry VN,Semple SI,Gibert FJ,et al. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer[J].Gynecol Oncol,2008,111(2):213-220.DOI:10.1016/j.ygyno.2008.07.048. [5] Kato H,Kanematsu M,Tanaka O,et al. Head and neck squamous cell carcinoma:usefulness of diffusion-weighted MR imaging in the prediction of a neoadjuvant therapeutic effect[J].Eur Radiol,2009,19(1):103-109.DOI:10.1007/s00330-008-1108-5. [6] King AD,Mo FKF,Yu KH,et al. Squamous cell carcinoma of the head and neck:diffusion-weighted MR imaging for prediction and monitoring of treatment response[J].Eur Radiol,2010,20(9):2213-2220.DOI:10.1007/s00330-010-1769-8. [7] Aoyagi T,Shuto K,Okazumi S,et al. Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer[J].Dige Surg,2011,28(4):252-257.DOI:10.1159/000328770. [8] Wang L,Han C,Zhu S,et al. Investigation of using diffusion-weighted magnetic resonance imaging to evaluate the therapeutic effect of esophageal carcinoma treatment[J].Oncol Res Treat,2014,37(3):112-116.DOI:10.1159/000360210. [9] van Rossum PSN,van Lier ALHMW,van Vulpen M,et al. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer[J].Radiother Oncol,2015,115(2):163-170. [10] Imanishi S,Shuto K,Aoyagi T,et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma[J].Dig Surg,2013,30(3):240-248.DOI:10.1159/000351435. [11] 陈伟,周胜利,苗重昌,等.DWMRI在食管癌同期放化疗早期疗效评价中的初步研究[J].中华放射肿瘤学杂志,2014,23(4):312-316.DOI:10.3760/cma.j.issn.1004-4221.2014.04.010. Chen W,Zhou SL,Miao CC,et al. Value of DWMRI for early assessment of response to concurrent chemoradiotherapy for esophageal cancer:a preliminary study[J].Chin J Radiat Oncol,2014,23(4):312-316.DOI:10.3760/cma.j.issn.1004-4221.2014.04.010. [12] 中国非手术治疗食管癌临床分期专家小组.非手术治疗食管癌的临床分期标准(草案)[J].中华放射肿瘤学杂志,2010,19(3):179-180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001. China non operative treatment of esophageal cancer clinical staging expert group. Standard for clinical staging of non operative treatment for esophageal cancer (Draft)[J].Chin J Radiat Oncol,2010,19(3):179-180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001. [13] 韩春,王澜,祝淑钗,等.非手术治疗食管癌临床分期标准对225例放疗患者的预后评价[J].中华放射肿瘤学杂志,2011,20(2):109-112.DOI:10.3760/cma.j.issn.1004-4221.2011.02.008. Han C,Wang L,Zhu SC,et al. Evaluation of prognosis of clinical staging for esophageal carcinoma treated with non-surgical methods-addition with analysis of 225 patients[J].Chin J Radiat Oncol,2011,20(2):109-112.DOI:10.3760/cma.j.issn.1004-4221.2011.02.008. [14] 王澜,孔洁,韩春,等.非手术治疗食管癌临床分期标准的临床应用与探讨[J].中华放射肿瘤学杂志,2012,21(4):330-333.DOI:10.3760/cma.j.issn.1004-4221.2012.04.012. Wang L,Kong J,Han C,et al. The evaluation of prognosis and investigation of clinical staging for esophageal carcinoma treated with non-surgical methods[J].Chin J Radiat Oncol,2012,21(4):330-333.DOI:10.3760/cma.j.issn.1004-4221.2012.04.012. [15] 李辉.食管癌术前分期的现状和进展[J].中华胸心血管外科杂志,2003,19(1):1-2.DOI:10.3760/cma.j.issn.1001-4497.2003.01.001. Li H.Current status and progress of preoperative staging of esophageal carcinoma[J].Chin J Thorac Cardiovasc Surg,2003,19(1):1-2.DOI:10.3760/cma.j.issn.1001-4497.2003.01.001. [16] 顾雅佳,王玖华,相加庆,等.CT观察胸段食管癌气管食管沟淋巴结转移的临床意义探讨[J].中华放射学杂志,2002,36(2):139-141.DOI:10.3760/j.issn:1005-1201.2002.02.014. Gu YJ,Wang JH,Xiang JQ,et al. A study on clinical value of CT features of tracheoesophageal groove lymph node metastasis of thoracic esophageal carcinoma[J].Chin J Radiolo,2002,36(2):139-141.DOI:10.3760/j.issn:1005-1201.2002.02.014. [17] 韩春,任雪姣,王澜,等.钡餐造影结合CT评价食管癌放疗近期疗效的研究[J].中华放射肿瘤学杂志,2013,22(1):26-29.DOI:10.3760/cma.j.issn.1004-4221.2013.01.008. Han C,Ren XJ,Wang L,et al. Evaluating short-term radiotherapeutic effect on esophageal cancer by barium meal combined with CT scans[J].Chin J Radiat Oncol,2013,22(1):26-29.DOI:10.3760/cma.j.issn.1004-4221.2013.01.008.
2016, Vol. 25 
